rhinovirusinduc
bronchial
mucos
eosinophil
neutrophil
macrophag
lymphocyt
copd
subject
relat
experiment
rhinovirusinduc
copd
exacerb
sever
antiviralantiinflammatori
therapi
could
attenu
bronchial
inflamm
amelior
virusinduc
copd
exacerb
sever
experiment
rhinoviru
infect
increas
bronchial
mucos
eosinophil
neutrophil
copd
subject
macrophag
lymphocyt
copd
noncopd
control
rhinovirusinduc
bronchial
mucos
inflamm
associ
ill
sever
virusinduc
copd
exacerb
antivir
antiinflammatori
therapi
could
attenu
bronchial
inflamm
amelior
virusinduc
copd
exacerb
abstract
background
respiratori
viral
infect
caus
chronic
obstruct
pulmonari
diseas
copd
exacerb
previous
report
increas
bronchial
mucosa
eosinophil
neutrophil
inflamm
copd
experienc
natur
occur
exacerb
unclear
whether
viru
per
se
induc
bronchial
mucos
inflamm
whether
relat
exacerb
sever
object
determin
extent
natur
bronchial
mucos
inflamm
follow
experiment
rhinoviru
rv
copd
exacerb
relationship
diseas
sever
method
bronchial
mucos
inflammatori
cell
phenotyp
determin
preinfect
baselin
follow
experiment
rv
infect
gold
stage
ii
copd
subject
control
smoker
nonsmok
normal
lung
function
subject
histori
asthmaallerg
rhiniti
neg
aeroallergen
skin
prick
test
result
rvinfect
increas
number
bronchial
mucos
eosinophil
neutrophil
copd
tlymphocyt
copd
nonsmok
monocytesmacrophag
tand
blymphocyt
increas
subject
baselin
compar
nonsmok
copd
subject
smoker
increas
number
bronchial
mucos
monocytesmacrophag
tlymphocyt
fewer
number
tand
blymphocyt
virusinduc
inflammatori
cell
copd
posit
associ
viru
load
ill
sever
reduct
lung
function
conclus
experiment
rhinoviru
infect
induc
bronchial
mucos
eosinophilia
neutrophilia
copd
monocytesmacrophag
lymphocyt
copd
control
subject
virusinduc
inflammatori
cell
phenotyp
observ
copd
posit
relat
viru
load
ill
sever
antiviralantiinflammatori
therapi
could
attenu
bronchial
inflamm
amelior
virusinduc
copd
exacerb
word
exacerb
chronic
obstruct
pulmonari
diseas
copd
major
caus
morbid
mortal
respiratori
viral
infect
major
caus
acut
exacerb
human
rhinovirus
rv
common
virus
detect
previous
report
studi
shown
experiment
rvinfect
subject
copd
induc
lower
respiratori
tract
symptom
airflow
obstruct
system
airway
inflamm
greater
prolong
compar
smoke
control
subject
without
airway
obstruct
indic
causal
relationship
rvinfect
copd
exacerb
copd
stabl
phase
characteris
airway
inflamm
central
pathogenesi
diseas
increas
number
airway
mucos
monocytesmacrophag
b
lymphocyt
neutrophil
associ
sever
airflow
limit
neutrophil
inflamm
classic
hallmark
stabl
copd
natur
occur
copd
exacerb
eosinophil
inflamm
whilst
usual
consid
characterist
featur
asthma
also
present
subset
copd
patient
stabl
exacerb
increas
number
mucos
eosinophil
detect
bronchial
biopsi
chronic
bronchiti
copd
subject
experienc
natur
occur
exacerb
howev
role
eosinophil
copd
exacerb
particularli
respiratori
virusinduc
exacerb
remain
unclear
unknown
whether
viru
infect
per
se
caus
mucos
eosinophilia
neutrophilia
copd
exacerb
also
number
confound
factor
aforement
studi
inclus
mechan
ventil
patient
receiv
oral
corticosteroid
prior
sampl
use
differ
patient
group
comparison
stabl
versu
exacerb
state
develop
experiment
model
copd
exacerb
use
human
infect
nonintub
copd
patient
part
two
complet
studi
use
model
bronchial
biopsi
collect
copd
patient
noncopd
smoker
nonsmok
baselin
prior
infect
day
acut
infect
sampl
provid
uniqu
opportun
explor
bronchial
mucos
inflammatori
respons
physiolog
clinic
signific
virusinduc
experiment
copd
exacerb
investig
whether
respons
differ
copd
patient
noncopd
subject
hypothesis
rhinoviru
infect
alon
recruit
inflammatori
cell
bronchial
mucosa
natur
inflammatori
respons
associ
sever
clinic
symptom
airflow
obstruct
subject
copd
distinct
seen
noncopd
subject
tabl
show
demograph
data
baselin
infect
studi
ie
success
infect
adequ
bronchial
biopsi
materi
analysi
name
smoker
gold
stage
ii
copd
fev
predict
normal
valu
fev
fvc
revers
smoker
normal
lung
function
fev
predict
fev
fvc
healthi
nonsmok
inclusionexclus
criteria
provid
tabl
articl
onlin
repositori
subject
nonatop
defin
neg
reaction
sixgrass
pollen
mix
skin
prick
test
none
histori
asthma
allerg
rhiniti
subject
symptom
respiratori
tract
infect
within
previou
week
copd
patient
exacerb
previou
month
subject
use
corticosteroid
either
inhal
system
antibiot
treat
exacerb
experiment
rv
infect
medic
allow
increas
use
shortact
agonist
subject
gave
inform
written
consent
studi
protocol
approv
st
mari
nh
trust
research
ethic
committe
studi
number
ten
tissu
cultur
infect
dose
tcid
administ
day
nasal
spray
previous
describ
rvinfect
confirm
least
one
follow
posit
nasal
lavag
sputum
bal
standard
qpcr
rv
posit
cultur
seroconvers
defin
titr
serum
neutral
antibodi
week
describ
peripher
blood
eosinophil
count
baselin
day
infect
sputum
sampl
baselin
day
duringpostinfect
detail
sputum
process
provid
previou
public
sputum
eosinophil
cytospin
count
mediat
eotaxin
interleukin
il
tnf
measur
use
mesoscal
platform
eosinophil
cation
protein
ecp
cathelicidin
neutrophil
elastas
measur
use
elisa
kit
accord
manufactur
instruct
bronchoscopi
clinic
data
bronchial
biopsi
taken
day
infect
baselin
day
infect
acut
infect
subject
day
infect
convalesc
copd
subject
smoke
control
neutrophil
elastas
neutrophil
eosinophil
tryptas
mast
cell
tand
blymphocyt
monocytesmacrophag
immunostain
previous
describ
slide
code
avoid
observ
bia
area
epithelium
epi
subepithelium
sub
assess
use
appl
macintosh
comput
imag
softwar
inflammatori
cell
seen
count
light
microscop
data
cell
count
express
number
posit
cell
per
mm
subepithelium
per
mm
epithelium
one
way
anova
follow
unpair
student
ttest
use
analys
age
smoke
pack
year
lung
function
data
group
respect
cell
count
blood
sputum
biopsi
mediat
sputum
data
nonnorm
distribut
overal
differ
group
three
time
point
within
group
assess
firstli
use
kruskalw
test
signific
follow
wilcoxon
match
pair
test
within
group
baselin
infect
group
differ
analys
mannwhitney
test
spearman
rank
correl
use
correl
number
inflammatori
cell
viru
loadphysiologicclin
datasputum
inflammatori
markersblood
eosinophil
p
valu
accept
statist
signific
detail
method
provid
articl
onlin
repositori
inflammatori
cell
present
bronchial
epiand
subcompart
repres
photograph
depict
fig
eosinophil
fig
elastas
neutrophil
fig
b
monocytesmacrophag
fig
c
fig
fig
e
tlymphocyt
fig
f
blymphocyt
appear
frequent
bronchial
mucosa
copd
day
postinfect
compar
baselin
fig
gl
applic
irrelev
antibodi
inflammatori
cell
marker
neg
fig
strike
increas
absolut
cell
count
day
postinfect
compar
baselin
copd
greater
increas
number
subeosinophil
p
fig
tabl
day
number
subeosinophil
copd
subject
significantli
higher
compar
nonsmok
p
copd
subject
nonsignific
trend
increas
subneutrophil
p
tabl
number
cell
significantli
increas
day
postinfect
baselin
three
group
p
fig
b
cell
increas
significantli
day
baselin
copd
nonsmok
group
p
respect
fig
c
count
copd
subject
smoker
significantli
higher
compar
nonsmok
day
p
respect
fig
c
count
significantli
increas
day
baselin
copd
smoker
group
p
fig
e
elev
number
subneutrophil
cell
copd
group
persist
week
remain
similar
median
level
count
day
tabl
wherea
subeosinophil
cell
return
respect
baselin
level
tabl
subtryptas
mast
cell
count
significantli
decreas
baselin
day
postinfect
smoker
copd
group
p
respect
fig
f
also
decreas
baselin
week
copd
p
tabl
tabl
epineutrophil
remain
significantli
higher
p
baselin
level
week
postinfect
tabl
number
cell
smoker
significantli
increas
day
baselin
p
fig
b
also
day
cell
count
smoker
significantli
higher
nonsmok
p
number
cell
increas
significantli
baselin
day
postinfect
three
group
p
fig
c
number
cell
day
smoker
copd
subject
significantli
higher
compar
nonsmok
group
p
respect
fig
e
elev
number
cell
smoker
copd
group
persist
week
remain
similar
level
count
day
tabl
signific
differ
count
epieosinophil
mast
cell
baselin
infect
subject
group
investig
differ
inflammatori
respons
nonsmok
smoker
copd
subject
rvinfect
magnitud
chang
inflammatori
cell
count
baselin
infect
compar
group
chang
number
subeosinophil
baselin
day
postinfect
copd
significantli
greater
chang
nonsmok
smoker
p
respect
fig
g
copd
subject
experienc
increas
exacerb
median
increas
eosinophil
mm
subepithelium
copd
vs
nonsmok
smoker
contrast
signific
differ
group
chang
baselin
day
phenotyp
inflammatori
cell
chang
blood
eosinophil
number
baselin
infect
subject
group
howev
small
statist
signific
increas
blood
eosinophil
percentag
copd
subject
baselin
day
vs
p
fig
control
subject
previous
report
signific
increas
sputum
eosinophil
two
studi
analys
separ
two
studi
combin
herein
signific
increas
baselin
either
sputum
eosinophil
number
percentag
day
infect
copd
subject
correl
mucos
eosinophil
blood
sputum
eosinophil
measur
chemokinescytokin
relev
eosinophil
biolog
sputum
subset
subject
suffici
sputum
supernat
remain
follow
infect
signific
increas
eotaxin
p
fig
b
p
p
fig
c
copd
subject
noncopd
control
data
shown
signific
increas
ecp
follow
infect
data
shown
correl
mucos
eosinophil
sputum
marker
number
subeosinophil
copd
infect
associ
peak
sputum
viru
final
examin
relationship
subeosinophil
number
day
postinfect
sputum
inflammatori
marker
previous
measur
copd
subject
subeosinophil
correl
peak
sputum
neutrophil
r
p
fig
signific
correl
subeosinophil
peak
sputum
eosinophil
subeosinophil
also
correl
strongli
peak
valu
infect
sever
sputum
inflammatori
mediat
antimicrobi
peptid
includ
r
p
fig
correl
epior
subneutrophil
sputum
inflammatori
marker
found
experiment
rv
infect
induc
eosinophil
neutrophil
copd
subject
wherea
macrophag
tand
blymphocyt
increas
copd
control
subject
statist
signific
posit
associ
found
inflammatori
cell
number
viru
load
respiratori
symptom
sever
reduct
lung
function
copd
number
subeosinophil
also
correl
inflammatori
marker
sputum
presenc
role
eosinophil
copd
exacerb
remain
unclear
conflict
result
studi
use
sputum
studi
report
increas
number
eosinophil
exacerb
includ
viru
detect
report
increas
sputum
eosinophil
restrict
virusinduc
sever
exacerb
found
signific
increas
eosinophil
number
virusinduc
exacerb
discrep
may
due
heterogen
aetiolog
copd
exacerb
time
sampl
effect
treatment
variat
diseas
sever
studi
use
bronchial
biopsi
report
increas
eosinophil
bronchial
mucosa
natur
occur
exacerb
role
virus
caus
mucos
eosinophilia
remain
uncertain
present
studi
first
compar
effect
experiment
administ
viru
bronchial
mucos
inflammatori
respons
use
bronchial
biopsi
subject
stabl
exacerb
nonintub
copd
subject
signific
increas
mucos
sputum
eosinophil
demonstr
copd
subject
follow
rv
infect
also
chang
subeosinophil
count
cell
type
baselin
day
infect
copd
subject
significantli
greater
nonsmok
smoker
control
subject
demonstr
clear
differ
mucos
inflammatori
respons
copd
noncopd
subject
moreov
greater
number
subeosinophil
associ
greater
viru
load
symptom
bigger
fall
lung
function
higher
sputum
inflammatori
marker
find
rvinduc
eosinophilia
noteworthi
given
observ
subject
rel
mild
copd
histori
asthma
allerg
rhiniti
test
neg
ten
aeroallergen
skin
prick
test
data
support
pathogen
role
bronchial
mucos
eosinophilia
rv
infectioninduc
copd
exacerb
therefor
exacerb
copd
eosinophil
identifi
steroid
eosinophiltarget
therapi
consid
addit
futur
novel
antivir
therapi
may
particular
benefit
addit
blood
eosinophil
examin
marker
guid
corticosteroid
use
copd
exacerb
though
approach
continu
debat
data
suggest
relationship
blood
sputum
mucos
eosinophil
complex
lack
relationship
blood
mucos
eosinophil
impli
use
blood
eosinophil
alon
marker
airway
mucos
eosinophilia
may
result
patient
without
blood
eosinophilia
receiv
corticosteroid
inde
mucos
eosinophilia
contrari
result
seen
eosinophil
subneutrophil
significantli
increas
wherea
epineutrophil
increas
copd
higher
number
posit
relat
viru
load
fall
lung
function
also
report
previous
neutrophil
significantli
increas
sputum
copd
subject
strong
correl
sputum
neutrophil
sputum
neutrophil
elastas
tnf
surprisingli
present
analys
sputum
marker
correl
better
subeosinophil
episubneutrophil
data
suggest
viru
infect
induc
innat
inflammatori
respons
involv
mediat
tnf
contribut
recruit
neutrophil
eosinophil
consid
neutrophil
transit
rapidli
blood
bronchial
mucos
airway
lumen
thu
number
sputum
reflect
mucos
tissu
neutrophil
inflamm
contrast
like
eosinophil
transit
slowli
retain
mucos
compart
thu
specul
contribut
eosinophil
may
well
underestim
studi
use
sputum
alon
moreov
therapi
target
eosinophil
focuss
th
pathway
asthma
copd
distinct
asthma
present
data
copd
show
associ
eosinophil
mediat
innat
inflamm
suggest
pathway
may
involv
eosinophil
recruit
airway
least
context
acut
viral
infect
earlier
studi
suggest
pathogen
role
monocytesmacrophag
cell
copd
mechan
increas
recruit
copd
well
known
previou
studi
demonstr
posit
correl
number
bronchial
mucos
cell
copd
number
pack
year
smoke
confirm
baselin
number
cell
significantli
greater
smoker
copd
nonsmok
baselin
count
copd
correl
posit
smoke
pack
year
addit
first
time
present
data
show
cell
increas
nonsmok
copd
baselin
follow
infect
smoker
significantli
higher
baselin
count
compar
nonsmok
baselin
contrast
rvinfect
induc
increas
cell
three
group
number
cell
significantli
greater
smoker
copd
group
nonsmok
group
day
postinfect
respect
week
cell
number
smoker
copd
still
increas
data
indic
smoke
viru
infect
addit
prolong
effect
pulmonari
recruit
cytotox
cell
previous
demonstr
cell
significantli
fewer
copd
stabl
phase
compar
nonsmok
control
howev
time
healthi
smoker
group
avail
comparison
gosman
et
al
report
increas
bronchial
mucos
b
lymphocyt
gold
stage
copd
compar
healthi
smoker
hogget
et
al
report
accumul
volum
bcell
small
airway
increas
stage
copd
increas
number
b
cell
associ
increas
sever
copd
last
healthi
nonsmok
group
includ
presenc
absenc
viru
infect
investig
either
aforement
studi
therefor
role
smoke
viru
infect
cell
recruit
bronchial
mucosa
remain
unclear
herein
report
first
time
smoker
copd
subject
lower
number
baselin
cell
compar
nonsmok
baselin
wherea
rvinfect
recruit
cell
bronchial
mucosa
three
group
find
indic
smoke
per
se
increas
cell
decreas
cell
wherea
rv
infect
increas
recruit
cell
type
bronchial
mucosa
subject
final
consid
reduct
number
submast
cell
like
due
infectioninduc
degranul
lead
fewer
cell
contain
suffici
tryptas
stain
posit
purpos
identif
effect
smoke
viru
infect
mast
cell
biolog
copd
exacerb
requir
studi
subject
rel
mild
gold
stage
ii
copd
suggest
sever
copd
popul
eosinophil
inflamm
may
even
promin
acknowledg
group
size
rel
small
particularli
sputum
eosinophil
mediat
thu
signific
correl
may
miss
furthermor
exploratori
hypothesisgener
studi
control
type
error
aris
multipl
comparison
result
observ
signific
differ
associ
may
subject
fals
posit
hypothesistest
studi
need
confirm
select
observ
howev
rel
homogen
subject
allow
reliabl
interpret
data
difficult
obtain
natur
occur
exacerb
copd
neutrophil
copd
wherea
monocytesmacrophag
tand
blymphocyt
increas
copd
noncopd
control
eosinophil
inflammatori
respons
rv
infect
bronchial
mucosa
copd
differ
seen
airway
lumen
blood
increas
number
inflammatori
cell
copd
correl
viru
load
ill
sever
eosinophil
also
associ
sputum
innat
inflammatori
mediat
infect
addit
chronic
cigarett
smoke
decreas
number
cell
increas
cell
thu
find
provid
new
insight
previous
undescrib
pattern
inflammatori
respons
occur
experiment
rvinduc
exacerb
copd
also
smoke
per
se
data
could
impact
design
futur
treatment
modal
postinfect
count
e
epiand
f
subneutrophil
day
prebronchodil
predict
day
spearman
rank
correl
n
tabl
two
smoker
group
two
studi
subject
nonatop
defin
neg
reaction
six
grass
pollen
mix
hous
dust
mite
cat
dog
aspergillu
fumigatu
cladosporium
herbarium
alternaria
alternata
birch
pollen
three
tree
pollen
mix
nettl
pollen
alk
abello
skin
prick
test
none
histori
asthma
allerg
rhiniti
protocol
two
studi
ident
total
subject
copd
smoker
nonsmok
inocul
lowdos
rhinoviru
subject
complet
studi
one
subject
copd
withdrew
ill
health
believ
unconnect
studi
rhinoviru
rv
infect
confirm
subject
copd
smoker
nonsmok
infect
subject
includ
present
biopsi
studi
bronchial
biopsi
obtain
one
copd
one
healthi
smoker
two
day
biopsi
obtain
two
copd
subject
one
day
biopsi
smoker
inadequ
qualiti
exclud
thu
actual
copd
healthi
smoker
healthi
nonsmok
pair
baselin
day
bronchial
biopsi
analys
subject
recruit
number
sourc
includ
newspap
advertis
primari
care
spirometri
clinic
smoke
cessat
clinic
outpati
hospit
clinic
initi
screen
visit
suitabl
studi
assess
inform
consent
obtain
subject
respiratori
tract
infect
within
previou
week
serum
neutral
antibodi
measur
screen
titr
copd
patient
exacerb
treat
oral
inhal
nasal
topic
steroid
longact
tiotropium
previou
month
enter
studi
baselin
clinic
sampl
perform
week
viru
inocul
studi
day
subject
seen
daili
day
immedi
inocul
timelin
clinic
measur
sampl
outlin
previou
paper
viru
inocul
detail
regard
prepar
safeti
test
inoculum
use
studi
publish
viru
tcid
dilut
total
volum
ml
salin
inocul
nostril
use
atom
devilbiss
co
heston
uk
collect
baselin
day
postinocul
blood
also
collect
day
obstruct
sore
throat
cough
grade
absent
sever
daili
cold
score
summat
individu
score
clinic
cold
defin
use
jackson
criteria
score
system
lower
respiratori
symptom
short
breath
cough
wheez
sputum
quantiti
sputum
qualiti
shown
previou
paper
daili
lower
respiratori
score
summat
individu
score
copd
exacerb
defin
increas
lower
respiratori
score
least
two
point
baselin
least
two
consecut
day
upper
lower
respiratori
daili
symptom
score
mean
score
day
calcul
subtract
subsequ
daili
score
correct
baselin
symptom
inc
usa
previous
describ
modif
subject
measur
count
order
take
account
within
subject
variabl
total
epitheli
subepitheli
area
two
three
biopsi
mm
mm
respect
accept
adequ
size
epitheli
subepitheli
area
posit
cell
two
three
biopsi
bronchoscopi
sum
respect
total
count
divid
total
area
normalis
count
number
cell
per
unit
area
data
bronchial
biopsi
cell
count
express
number
cut
cell
profil
nucleu
visibl
ie
posit
cell
per
mm
epitheli
area
per
mm
subepitheli
area
coeffici
variat
repeat
count
cell
immunoposit
subtyp
marker
inflammatori
cell
one
observ
rang
statist
analysi
perform
use
statview
sa
institut
inc
graphpad
prism
version
window
graphpad
softwar
san
diego
ca
one
way
anova
follow
unpair
student
ttest
use
analys
age
smoke
pack
year
lung
function
data
group
respect
cell
count
blood
sputum
biopsi
mediat
sputum
data
nonnorm
distribut
overal
differ
group
three
time
point
within
group
assess
firstli
use
kruskalw
test
signific
follow
wilcoxon
match
pair
test
within
group
baselin
infect
differ
group
analys
mannwhitney
test
coeffici
variat
cv
sdmean
use
express
error
repeat
cell
count
biopsi
spearman
rank
correl
use
test
correl
number
specif
type
inflammatori
cell
viru
loadphysiologicclin
datasputum
inflammatori
marker
pvalu
accept
indic
signific
differ
report
p
valu
twosid
copd
individu
viru
load
peak
day
nasal
lavag
day
sputum
day
bal
individu
lower
respiratori
symptom
breathless
score
peak
around
day
individu
lowest
pef
fev
detect
day
day
day
virolog
blood
sputum
bal
inflammatori
data
subject
report
previous
associ
number
mucos
monocytesmacrophag
lymphocyt
viru
load
clinic
outcom
viru
load
copd
day
postinfect
number
cell
associ
peak
nasal
lavag
viru
load
r
p
respect
fig
b
cell
correl
peak
sputum
viru
load
r
p
fig
c
cell
correl
bal
viru
load
r
p
fig
copd
subject
higher
count
day
postinfect
significantli
greater
peak
breathless
score
r
p
respect
fig
b
count
day
correl
posit
peak
lower
respiratori
symptom
score
record
day
r
p
fig
c
copd
higher
number
cell
day
significantli
associ
lower
prebronchodil
fev
predict
day
r
p
fig
df
